Smallpox vaccine - Bavarian Nordic

Drug Profile

Smallpox vaccine - Bavarian Nordic

Alternative Names: IMVAMUNE; IMVAMUNE® liquid-frozen; IMVAMUNE® freeze-dried; IMVANEX; MVA-BN® Smallpox

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Centers for Disease Control and Prevention
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Smallpox
  • Phase III Monkeypox

Most Recent Events

  • 23 Feb 2017 Phase-III clinical trials in Monkeypox (Prevention) in Democratic Republic of the Congo (SC) (NCT02977715)
  • 23 Nov 2016 Bavarian Nordic completes enrolment in a phase III trial in Smallpox (Prevention) in South Korea
  • 20 Jul 2015 IMVAMUNE® is still in phase II trials for Smallpox (Prevention, In children, In infants) in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top